Moderna and Merck: What early melanoma data leave open
Reports of prematurely published trial figures are moving markets. For patients, what counts is the full results of the announced phase 3 analysis.
Reports of preliminary leaked results from a melanoma trial turned attention on Moderna and US pharmaceutical group Merck on 22 October. The industry service FirstWord Pharma reported, citing Investor’s Business Daily, a suspected early access to data and falling share prices. The origin and completeness of these details therefore remain unverified independently. This report does not establish a hacker attack or the theft of personal patient data.
What is confirmed is where the medical expectation is directed. A presentation of the phase 3 trial INTerpath-001 is scheduled for 24 October at the European cancer congress ESMO in Madrid. It investigates the individually manufactured mRNA therapy intismeran autogene together with the immunotherapy drug pembrolizumab in people whose melanoma has been completely removed. The treatment is intended to lower the risk of recurrence after surgery.
An add-on therapy after surgery
The trial covers high-risk patients with cutaneous melanoma of stages IIB to IV after complete removal of the tumour. The combination is compared with pembrolizumab and placebo. The study centre MD Anderson describes the investigation as randomised and double-blind: allocation is by chance, and blinding is meant to limit the influence of expectations on treatment and assessment.
Intismeran autogene is not a general vaccine against any cancer. According to the developers, the therapy is tailored to the mutation pattern of the respective tumour. The mRNA is intended to give the immune system features by which it can recognise cancer cells. That description explains the concept. Whether and how much patients benefit must be shown by the clinical analysis.
What the companies have already disclosed
Merck and Moderna reported on 19 August that the phase 3 trial had met its efficacy goals for recurrence-free and distant metastasis-free survival. These were so-called topline results, an initial condensed announcement of results. Such an announcement is relevant but does not automatically contain all the figures, subgroups, confidence intervals and adverse event data needed for an independent assessment.
The congress announcement published on 21 September gives the presentation slot as Saturday, 24 October, at 16.30 Central European Summer Time. Outside the US and Canada, Merck is known as MSD. That also matters for Swiss readers: the reference is to Moderna’s American development partner, not the German group of the same name.
Why a percentage alone is not enough
A lower recurrence risk is an important result for those affected. It nonetheless answers a different question than overall survival. In its assessment of cancer trials, the US National Cancer Institute explicitly distinguishes between study design and the endpoint measured. Quality of life, side effects and the length of follow-up can also change the practical significance of a finding.
The reference base matters too. A relative risk reduction describes the difference between groups relative to each other. For treating an individual person, it also matters how many people in both groups were actually affected and over what period. Without these details, a percentage must not be translated into a probability of cure or a guaranteed number of prevented relapses.
That is why the figures supposedly circulated in advance are not reproduced here as established trial results. A robust assessment requires the full presentation and the accompanying documents. Even then, possible limits of individual subgroups and longer observation periods remain to be considered.
What this means for patients in Switzerland
A falling share price can express disappointed investor expectations. It is neither medical proof of efficacy nor evidence that a therapy has failed. Likewise, meeting a trial endpoint does not automatically mean approval, availability or reimbursement in Switzerland. Those are separate decisions and procedures.
For patients, the next serious point of orientation is therefore the full analysis, not share market reports circulated in advance. What will matter is the additional benefit the combination brings for the patient group studied, what burdens are associated with it and how certain these statements are. A new treatment deserves hope based on robust data – and an assessment that reads benefits and limits with equal care.
Sources
- Merck and Moderna: phase 3 topline announcement of 19 August 2026
- Moderna: ESMO presentation programme, original release via Nasdaq
- MD Anderson Cancer Center: trial description INTerpath-001
- National Cancer Institute: levels of evidence and endpoints in cancer trials
- FirstWord Pharma: report on allegedly pre-circulated data
